As the scarce target of the global RNA track, will Sirnaomics, which is heard by Hong Kong stocks, become the first stock of nucleic acid drugs?

Sirnaomics grabs the opportunity of "the first stock of domestic nucleic acid drugs" and has the attribute of absolute scarcity.

格隆滙Dec 17, 2021 09:37

Sirnaomics Strengthens Its Development and Manufacturing Leadership with Promotions of Two Biopharma Veterans, Dr. Steven Long and Dr. Edward Wang

PR NewswireDec 15, 2021 09:56

Hong Kong Stock IPO Weekly report | Propranolol Biological, San Nuo Pharmaceuticals passed the hearing, Bowei Smart Technology and other three new shares delivery form

In the Hong Kong stock IPO market, there were no new offerings, 2 new shares passed the hearing and 3 new shares were submitted this week. In terms of fund-raising, as of December 12, 2021, 88 new shares (excluding one REITs) were listed in Hong Kong this year, raising a total of HK $313.628 billion. What is worth paying attention to this week is that the intrusive cardiovascular device company Prozac and the domestic "small nucleic acid drug first unit" San Nuo Pharmaceuticals have been heard by the Hong Kong Stock Exchange; Bowei Smart Technology, which ranks first in the market for IT solutions in Macau, has submitted its form to the Hong Kong Stock Exchange. 1 the IPO period is not new this week

格隆滙Dec 12, 2021 23:19

Weekly IPO | A number of star companies sprinted to the Hong Kong Stock Exchange, and Weibo successfully returned to Hong Kong for a second listing

Popular IPOs such as Yonghe Medical and SF Express Tongcheng will make a group appearance next week; Baixinan, Jinli Permanent Magnet, and Shengnuo Pharmaceutical, the “first small nucleic acid drug” in China, passed the hearing.

富途資訊Dec 11, 2021 22:02 · IPO

Shengnuo Pharmaceutical, the first RNA therapy stock, passed the hearing on the Hong Kong Stock Exchange and has completed 7 rounds of financing of nearly 270 million US dollars

Dec 8, 2021 10:52

mRNA vaccine and drug development company Dawan Biotech quickly starts mRNA vaccine research and development targeting the COVID-19 Omicron strain

Dec 8, 2021 10:51